Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.45 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.45 |
| ▸ | PNP | P00491 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14628598 | 0.87 | HIF1A (0.60) | HIF1APNPLMNATP53HTT | |
| SCHEMBL21423035 | 0.87 | HIF1A (0.60) | HIF1APNPLMNATP53HTT | |
| SCHEMBL13058825 | 0.87 | HIF1A (0.60) | HIF1APNPLMNATP53HTT | |
| SCHEMBL19666769 | 0.87 | HIF1A (0.60) | HIF1APNPLMNATP53HTT | |
| SCHEMBL20908479 | 0.83 | TAS1R3 (0.48) | TAS1R3TAS1R1P2RX3P2RX2 | |
| SCHEMBL5198998 | 0.79 | HIF1A (0.56) | HIF1A | |
| SCHEMBL5199003 | 0.79 | HIF1A (0.56) | HIF1A | |
| SCHEMBL20908480 | 0.79 | ALDH1A1 (0.58) | TAS1R3TAS1R1P2RX3P2RX2LMNA | |
| SCHEMBL21263874 | 0.78 | TAS1R3 (0.60) | TAS1R3TAS1R1HIF1AP2RX3P2RX2 | |
| SCHEMBL20908769 | 0.78 | TAS1R3 (0.58) | TAS1R3TAS1R1HIF1AP2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10519187-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190248828-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519187-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | TAS1R3 4686/4885TAS1R1 4753/4885HIF1A 2264/4885 |
| US-20190248828-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | TAS1R3 4686/4885TAS1R1 4753/4885HIF1A 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.